Last updated on March 2020

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for Multiple Sclerosis (MS)


Brief description of study

The purpose of this study is to explore the long-term outcomes, durability of effect, and real world treatment patterns in participants previously participating in the Phase 3 oral cladribine in early multiple sclerosis (ORACLE MS) and Oral Cladribine in participants with relapsing remitting multiple sclerosis, extension study (CLARITY/CLARITY-EXT) clinical trials with the study number of 28821 (NCT00725985), 25643 (NCT00213135) and 27820 (NCT00641537) respectively.

Clinical Study Identifier: NCT03961204

Find a site near you

Start Over
Sorry. There are no research sites conducting this study in the radius provided. ( View all Sites )
If you would like to be informed of other studies that may be of interest to you, you may sign up for CenterWatch.com's Patient Notification Service.